Drugs / PB103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04616209 | Nov 2020 → Dec 2027 expected | non-small cell lung carcinoma | Precision Biotech Taiwan Corp. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB103 | “PB103 is allogeneic NK cells derived from a healthy donor.” NCT04616209 ↗ |
| Modality | Cell therapy | “PB103 is allogeneic NK cells derived from a healthy donor.” NCT04616209 ↗ |